Allergy, Asthma & Respiratory Disease

The Korean Academy of Asthma, Allergy and Clinical Immunology (대한천식알레르기학회)
권호 표지
DOI QR코드

DOI QR Code

Acute generalized exanthematous pustulosis caused by dihydrocodeine or codeine: A case-based review

사례 중심으로 살펴본 dihydrocodeine 또는 codeine을 복용 후 발생한 급성 전신 발진성 농포증

  • Jiung Jeong (Department of Internal Medicine, School of Medicine, Kyungpook National University) ;
  • Sujeong Kim (Department of Internal Medicine, School of Medicine, Kyungpook National University)
  • 정지웅 (경북대학교 의과대학 내과학교실) ;
  • 김수정 (경북대학교 의과대학 내과학교실)
  • Received : 2024.07.03
  • Accepted : 2024.08.05
  • Published : 2024.10.30
Download PDF
⟨ Previous Next ⟩

Abstract

Dihydrocodeine is an effective antitussive agent that inhibits the cough reflex by interacting with opioid receptors in the brain. It is easily available in pharmacies without a prescription, which may contribute to a lack of awareness about potential drug hypersensitivity reactions. In the first reported case in Korea, a 29-year-old man developed acute generalized exanthematous pustulosis (AGEP) after consuming an over-the-counter cold medicine containing dihydrocodeine. He was admitted to the Emergency Department with high fever and full-body skin rashes that appeared 3 hours after taking the medicine. His EuroSCAR AGEP score was 9, with symptoms improving upon discontinuation of dihydrocodeine and the application of topical steroids. AGEP caused by dihydrocodeine, including codeine, is very rare, with 3 cases reported worldwide. By analyzing AGEP cases due to dihydrocodeine or codeine, we identified that risk factors for the development of AGEP from dihydrocodeine include a history of psoriasis and the presence of an IL36RN mutation, which result in the activation of Th17 in the blood or the skin. In cases of AGEP caused by dihydrocodeine, it is also recommended to discontinue codeine due to cross-reactivity with dihydrocodeine. Additionally, patients with AGEP due to dihydrocodeine may be able to use other opioid classes, such as morphine or tramadol, due to low cross-reactivity.

Keywords

Acknowledgement

This research was supported by a grant from Ministry of Food and Drug Safety to operation of the regional pharmacovigilance center in 2024.

References

  1. Szatkowski J, Schwartz RA. Acute generalized exanthematous pustulosis (AGEP): a review and update. J Am Acad Dermatol 2015;73:843-8.
  2. Sidoroff A, Halevy S, Bavinck JN, Vaillant L, Roujeau JC. Acute generalized exanthematous pustulosis (AGEP)--a clinical reaction pattern. J Cutan Pathol 2001;28:113-9.
  3. Parisi R, Shah H, Navarini AA, Muehleisen B, Ziv M, Shear NH, et al. Acute generalized exanthematous pustulosis: clinical features, differential diagnosis, and management. Am J Clin Dermatol 2023;24:557-75.
  4. Hotz C, Valeyrie-Allanore L, Haddad C, Bouvresse S, Ortonne N, Duong TA, et al. Systemic involvement of acute generalized exanthematous pustulosis: a retrospective study on 58 patients. Br J Dermatol 2013;169:1223-32.
  5. Roujeau JC. Clinical heterogeneity of drug hypersensitivity. Toxicology 2005;209:123-9.
  6. Oh DAQ, Yeo YW, Choo KJL, Pang SM, Oh CC, Lee HY. Acute generalized exanthematous pustulosis: epidemiology, clinical course, and treatment outcomes of patients treated in an Asian academic medical center. JAAD Int 2021;3:1-6.
  7. Hadavand MA, Kaffenberger B, Cartron AM, Trinidad JCL. Clinical presentation and management of atypical and recalcitrant acute generalized exanthematous pustulosis. J Am Acad Dermatol 2022;87:632-9.
  8. Kim SH, Lee SY, Choi YH, Kim CH, Hyun IK, Choi JH. Radiocontrast media-induced acute generalized exanthematous pustulosis: a safe administration of alternative radiocontrast media using patch tests. Allergy Asthma & Respiratory Disease 2018;6:270-3.
  9. Lim HJ, Jung JH, Kim MJ, Kim JM, Kang HR, Song YK, et al. Acute generalized exanthematous pustulosis due to hydroxychloroquine in a rheumatoid arthritis patient. Allergy Asthma Respir Dis 2013;1:176-8.
  10. Kim HW, Choi YS, Won JH, Lee JM, Heo JY, Choi JA, et al. Acute generalized exanthematous pustulosis presumed to be caused by acetaminophen. Allergy Asthma Respir Dis 2017;5:52-5.
  11. Nakai N, Sugiura K, Akiyama M, Katoh N. Acute generalized exanthematous pustulosis caused by dihydrocodeine phosphate in a patient with psoriasis vulgaris and a heterozygous IL36RN mutation. JAMA Dermatol 2015;151:311-5.
  12. Chadli Z, Ladhari C, Kerkeni E, Djobbi A, Fredj NB, Chaabane A, et al. Codeine-induced acute generalized exanthematous pustulosis without IL36RN mutations. Pharmacogenomics 2018;19:889-93.
  13. Prasinou M, Bisconti I, Leck C, Billahalli T, Barnett S, Rajakulasingam K, et al. Acute generalized exanthematous pustulosis due to codeine confirmed by patch testing, without cross-reactivity to other opioids. J Allergy Clin Immunol Pract 2022;10:3029-31.
  14. Chung KF, McGarvey L, Song WJ, Chang AB, Lai K, Canning BJ, et al. Cough hypersensitivity and chronic cough. Nat Rev Dis Primers 2022;8:45.
  15. Hirai R, Uesawa Y. Analysis of opioid-related adverse events in Japan using FAERS Database. Pharmaceuticals (Basel) 2023;16:1541.
  16. Le H, Hong H, Ge W, Francis H, Lyn-Cook B, Hwang YT, et al. A systematic analysis and data mining of opioid-related adverse events submitted to the FAERS database. Exp Biol Med (Maywood) 2023;248:1944-51.
  17. Yoo HS, Yang EM, Kim MA, Hwang SH, Shin YS, Ye YM, et al. A case of codeine induced anaphylaxis via oral route. Allergy Asthma Immunol Res 2014;6:95-7.
  18. Gastaminza G, Audicana M, Echenagusia MA, Uriel O, Garcia-Gallardo MV, Velasco M, et al. Erythrodermia caused by allergy to codeine. Contact Dermatitis 2005;52:227-8.
  19. Iriarte Sotes P, Lopez Abad R, Gracia Bara MT, Castro Murga M, Sesma Sanchez P. Codeine-induced generalized dermatitis and tolerance to other opioids. J Investig Allergol Clin Immunol 2010;20:89-90.
  20. Nakamizo S, Kobayashi S, Usui T, Miyachi Y, Kabashima K. Clopidogrelinduced acute generalized exanthematous pustulosis with elevated Th17 cytokine levels as determined by a drug lymphocyte stimulation test. Br J Dermatol 2010;162:1402-3.
  21. Kabashima R, Sugita K, Sawada Y, Hino R, Nakamura M, Tokura Y. Increased circulating Th17 frequencies and serum IL-22 levels in patients with acute generalized exanthematous pustulosis. J Eur Acad Dermatol Venereol 2011;25:485-8.
  22. Nograles KE, Zaba LC, Guttman-Yassky E, Fuentes-Duculan J, SuarezFarinas M, Cardinale I, et al. Th17 cytokines interleukin (IL)-17 and IL22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol 2008;159:1092-102.
  23. Cornwell WD, Lewis MG, Fan X, Rappaport J, Rogers TJ. Effect of chronic morphine administration on circulating T cell population dynamics in rhesus macaques. J Neuroimmunol 2013;265:43-50.
  24. Mizukawa I, Kamata M, Shimizu T, Ito M, Watanabe A, Uchida H, et al. Expression of interleukin-36 receptor antagonist in a patient with generalized pustular psoriasis harboring the p.Pro82Leu variant in the IL36RN gene. J Dermatol 2023;50:1608-13.
  25. Adi G, Shaath MR, Adi K, Obaid Z, Aldosari E, AlKateb FA. Generalized pustular psoriasis in a toddler with IL36RN mutation: a case report. Front Immunol 2024;15:1337799.
  26. Sugiura K, Takemoto A, Yamaguchi M, Takahashi H, Shoda Y, Mitsuma T, et al. The majority of generalized pustular psoriasis without psoriasis vulgaris is caused by deficiency of interleukin-36 receptor antagonist. J Invest Dermatol 2013;133:2514-21.
  27. Takahashi T, Fujimoto N, Kabuto M, Nakanishi T, Tanaka T. Mutation analysis of IL36RN gene in Japanese patients with palmoplantar pustulosis. J Dermatol 2017;44:80-3.
  28. Smith HS. Opioid metabolism. Mayo Clin Proc 2009;84:613-24.
  29. Powell MZ, Mueller SW, Reynolds PM. Assessment of opioid cross-reactivity and provider perceptions in hospitalized patients with reported opioid allergies. Ann Pharmacother 2019;53:1117-23.